Wall Street Researcher

UNDERVALUED STOCK ALERT

CURE PHARMACEUTICAL HOLDING CORP

CURR

UPDATE

 Register And Listen To Conf Call And Webcast - Wed Aug 3, 2022 - 4 PM EDT  - Details Below

CURR announces Weds 4 PM Webcast & important business update confirming international discussions with parties for additional non-dilutive transactions as well as discussions with parties in the clinical development of molecule delivery technologies

Press Release can be found at the bottom of this report

Last week we published a detailed report on CURR after they received $20 million cash for a small portion of their IP related to pharma side of the business. We urged investors to consider purchase into further detail and a business update and webcast this week. The stock is rallying today after a press release came out detailing the Weds 4 PM Eastern webcast and more importantly provided an update in layman’s terms deciphering a confusing and complicated 8K full of patent and legal terms. Importantly, the company confirmed that they are in active international discussions that appear to have been going on for a long time and earlier stage discussions as well regarding licensing of the molecule delivery technologies with multiple parties.

Last Week’s WSR report:

http://www.wallstreetresearcher.com/Biotech/A%20TRADER%20CURR%207-28-22.html 

o CURR confirms they are in later stage international deal discussions as well as addition discussions with other parties to further monetize its IP and close additional non-dilutive transactions - Importantly this confirms our thesis – CURR just received about their TOTAL MARKET CAP PRE-DEAL with the $20 million cash transaction, avoiding a deeply discounted secondary which investors feared. Now its clear, they are trying to close multiple other non-dilutive cash transactions which in our opinion, if consummated will further validate their strategy to “execute on its strategy of being a broad platform technology company, creating new innovative technology and intellectual property with the intention of monetizing the pipeline and building “The Sera Labs brands that build shareholder value in the future including through further non-dilutive funding transactions”  (from today’s press release)

o An innovative holding company incubator with a respected wellness and beauty brand with Top 5 actress Nicole Kidman as their main spokesperson now with the capital to market this brand. To us this puts this investment in a whole new positive category of a holding company with multiple assets they are actively pursuing non-dilutive cash deals on as well intention to create new non-pharma products (we think melt on your tongue nicotine could be explored for instance) and with an innovative  wholly-owned subsidiary The Sera Labs, “a developer and marketer of wellness and beauty products, with its portfolio of brands and product lines including CBD based and non-CBD based now has the working capital to relaunch and build the Seratopical Revolution line. The Company recently shipped to over 1,200 Walmart (WMT) stores as well as to CVS and Bed, Bath and Beyond (BBBY) and looks to aggressively grow Seratopical Revolution into a global brand”.

o Mexico is about to launch - Authorization to sell Nutri-Strips products in Mexico was recently announced and the company expects to have sales this yr and including the 1^st edible CBD product in Mexico history.

o Company mentions important pet category in PR – CURR management has in past presentations mentioned the pet category and their desire to move to melt on your tongue OTF pet medicines. Anyone with a dog or cat understand how difficult it is to get them to take pills. A good tasting melt on your tongue pet medicine strip could have an enormous market in the pet medicine category and we know from previous comments management has discussed licensing. Now the company will have the time and resources to pursue this area more vigorously.

o CURR is in current discussions to replace Canopy Growth (CGC) CBD distribution agreement in the near term - Now free from the Canopy Growth (CGC) CBD distribution agreement, the company is almost certainly in discussions with other companies related to possible licensing of the company’s CBD technology and portfolio. Importantly, just to get out of the agreement, CGC paid almost $4 million to CURR to terminate the relationship after STZ overpaid and invested billions in CGC at ridiculous valuations. Some investors think the first CBD licensing agreement from here could bring in $10 million or more.

o CURR “will continue to invest in the clinical development of other molecule delivery technologies and is engaged in exploratory discussions with other third parties” Importantly this includes the red-hot area of psychedelics and many other areas.

Related Press Release: CURE Pharmaceutical Launches Psychedelic Oral Film Program Targeting the Treatment of Mental Health Disorders - CURE Pharmaceutical

o Send in your CURR questions for the Weds 4 PM EDT webcast by 11 am Tuesday The Company is accepting questions from shareholders that will be answered on the call. If you are interested in submitting questions, please email them to investor@curepharmaceutical.com by 11:00am Eastern Time Tuesday.

As we emphasize in our last report:, It’s Important to understand that this public company still also owns multiple patents in many areas including cannabis, CBD, psychedelics, extraction, and topicals and it still intends to be a broad platform technology company continuing to create and monetize new innovative technology and intellectual property with the intention to monetize the current and future pipeline it develops while continuing to work on the items both outside and inside The Sera Labs noted above.  While Rob Davidson is no longer CEO, he is one of the company’s largest shareholders, will remain on the board of directors and will work up to 25 hours (about 3 days) a week to continue to help the company continue its history of developing new and innovative products and help monetize them as well as continue partnering and licensing discussions in many of the areas noted above that are ongoing.

CURR is a strong buy as the cash need overhang has been completely removed, into the above positive catalysts with strong fundamentals, and balance sheet aligning right now after the most important transaction in the company’s history has brought validation of the company’s proprietary technology and cash to invest in the rest of the company’s exciting product pipeline. Importantly there is so much more left in the company besides The Sera Labs, which itself should see significant growth over the coming year.  We believe CURR at the current value is a compelling buy into the detail of Weds conference call, an enhanced marketing effort at The Sera Labs with respect to the Nicole Kidman “Revolution” line and other products, and additional non-dilutive deals that could bring more non-dilutive cash over the coming months

Full Press Release

 Cure Pharmaceutical Holding Corp.

Updates on Recent Transaction and Business will be Provided

OXNARD, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- CURE Pharmaceutical Holding Corp. (OTC: CURR) (“CURE”), a proprietary platform technology company, today announced that the Company will be hosting a teleconference with management on Wednesday, August 3, 2022, at 4:00 pm Eastern Time to discuss the recent $20 million non-dilutive sale of a small portion of its product and intellectual property portfolio and to provide a business update.

As a business update we would like to note the following with respect the public entity currently trading under the CURR symbol which will be expanded upon during the teleconference:

• The Company retained its exclusive rights to all Nutraceutical Nutri-Strip branded products and will continue to develop future products using the technology, including innovative IP in the beauty and pet categories.
• The Company owns the rights to a robust family of patents in many areas including, CBD, Cannabis, psychedelics, extraction, topicals and other Phyto Nutrient actives and is actively pursuing international transactions to monetize the IP with interested parties. There can be no assurances that we can consummate a transaction under terms acceptable to the company, but we will continue to work with these and other interested parties.
• The Company will continue to invest in the clinical development of other molecule delivery technologies and is engaged in exploratory discussions with other third parties. with interest in partnering these assets and while there is definite interest there is no guarantee that those discussions will lead to a partnership.
• The Company’s wholly-owned subsidiary The Sera Labs, Inc., a developer and marketer of wellness and beauty products, with its portfolio of brands and product lines including CBD based and non-CBD based now has the working capital to relaunch and build the Seratopical Revolution line. The Company recently shipped to over 1,200 Walmart (WMT) stores as well as to CVS and Bed, Bath and Beyond (BBBY) and looks to aggressively grow Seratopical Revolution into a global brand.

As will be further discussed on the teleconference, the Company intends to execute on its strategy of being a broad platform technology company, creating new innovative technology and intellectual property with the intention of monetizing the pipeline and building the The Sera Labs brands that build shareholder value in the future including through further non-dilutive funding transactions.

The Company is accepting questions from shareholders that will be answered on the call. If you are interested in submitted questions, please email them to investor@curepharmaceutical.com by 11:00am Eastern Time, Tuesday . We look forward to sharing more detail at this exciting time on the teleconference.

Neither PSN or WSR nor its owners, members, officers, directors, partners, consultants, nor anyone involved in the publication of this website, is a registered investment adviser or broker-dealer or associated person with a registered investment adviser or broker-dealer and none of the foregoing make any recommendation that the purchase or sale of securities of any company profiled in the PSN or WSR website is suitable or advisable for any person or that an investment or transaction in such securities will be profitable. The information contained in the PSN  or WSR website is not intended to be, and shall not constitute, an offer to sell nor the solicitation of any offer to buy any security. The information presented in the PSN  or WSR website is provided for informational purposes only and is not to be treated as advice or a recommendation to make any specific investment. Please consult with an independent investment adviser and qualified investment professional before making an investment decision.. All Reports are reviewed for accuracy and concur that any conclusions made are reasonable expectations. The term Buy List referring to a Watch List and not a recommendation to buy . Each individual has their own risk level and should know their risk level and act accordingly Shareholders confered and wrote this report after a CEO interview   .Distributer and WSR did not get paid